Compare GSK plc (GSK) vs Workday Inc (WDAY) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

WDAY trades at $145.46, up 4.04% in the last session, with a bullish technical signal from moving averages and a consensus analyst price target of $157.30. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $2.62. Revenue growth remains robust, projected to reach $9.9 billion in 2026, while net income margin improved to 8.6% in 2025. Recent news highlights AI-driven expansion deals and partnership growth, though the stock faces a lawsuit over AI bias concerns.

WDAY presents a favorable risk-reward profile with strong fundamentals and analyst support, but investors must weigh competitive pressures and regulatory risks. The stock's current valuation at 44.18x P/E reflects growth expectations, yet persistent net cash outflows and high debt levels warrant caution. Upside potential hinges on execution of AI initiatives and sustained subscription revenue growth amid a volatile tech sector.